Navigation Links
New Aptivus(R) (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
Date:6/24/2008

APTIVUS Oral Solution Also Approved for Treatment-Experienced Adult

Patients

RIDGEFIELD, Conn., June 24 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted approval of Aptivus(R) (tipranavir) capsules/oral solution with dosing information for treatment-experienced pediatric patients between the ages of 2-18 infected with HIV-1. The oral solution formulation, which is a new dosage form of APTIVUS, was also approved for treatment-experienced adults. The oral solution formulation will be available in the U.S. beginning in mid-September. The FDA granted full (traditional) approval to APTIVUS capsules for treatment-experienced adults in October 2007.

"Due to significant advances in HIV therapy and care, many perinatally infected children are growing into young adulthood and beyond. Most of these children have received multiple courses of anti-HIV medications and many have evidence that their HIV strains have developed resistance to the majority of currently approved antiretrovirals. An unmet need remains for pediatric indications and new formulations of antiretroviral therapies," said Dr. Juan Salazar, Associate Professor in Pediatrics, University of Connecticut's Department of Pediatrics, Division of Pediatric Infectious Diseases, and Director of the Pediatric and Youth HIV Program at the Connecticut Children's Medical Center. "This approval is an important development for treatment-experienced children and teenagers who may have limited therapeutic options."

APTIVUS Indications and Usage

APTIVUS, a protease inhibitor co-administered with ritonavir (APTIVUS/r), is indicated for combination antiretroviral treatment of HIV-1 infected patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on analyses of plasma HIV-1 RNA levels in t
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
3. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
4. BioLife Solutions Expands Scientific Advisory Board
5. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
6. Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management
7. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
8. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
9. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
10. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
11. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Palatin,Technologies, Inc. (Amex: PTN ) announced today ... PL-3994, a novel, long-acting natriuretic peptide,receptor A (NPRA) ... heart failure (CHF). The Phase I trial was ... 26 healthy volunteers who received the medication or ...
... AutoGenomics, a leader in,developing automated molecular testing solutions, ... healthcare and biotechnology companies presenting,at the 28th Annual ... at the,Boston Marriott Copley Place in Boston, Massachusetts. ... an overview of the,company, its automated molecular testing ...
... Protection Agency (EPA) to fine California technology company IOGEAR ... applauded by David Rejeski, the director of the Project ... big pat on the back for making this effort, ... that has been on the books for decades can ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:4/18/2014)... a twist to the story of how barnyard chickens came ... in the journal Proceedings of the National Academy of ... that lived 200-2300 years ago in Europe, researchers report that ... looked far different from the chickens we know today. , ... with modern domestic chickens -- such as their yellowish skin ...
(Date:4/18/2014)... Calif. A team of researchers led by ... been selected to receive a $7.5 million Department of ... simple and basic scientific foundations for the predictable design ... a wide diversity of structures from plants and animals, ... are taking what biological systems have constructed over millions ...
(Date:4/17/2014)... peptide inhibits RSV infection , Respiratory syncytial ... respiratory tract infections, generating life-threating illness in very ... therapies are limited. RSV enters host cells through ... six-helix fusogenic bundle. Small interfering peptides that prevent ... these peptides are highly susceptible to degradation. In ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... from the p53 Laboratory of Singapore,s Agency for Science, Technology ... a unique method of cancer treatment. Their work, published online ... today , offers new insight on how to tap on ... to more effectively kill cancer cells while sparing normal cells. ...
... Scientists have caught male topi antelopes in the act of faking ... improve their chances of having sex. The male antelopes, observed ... nearby only when females in heat are in their territories. When ... long enough for some males to fit in a quick mating ...
... May 24 BIO-key International, Inc. (OTC Bulletin Board: BKYI), ... has integrated BIO-key,s biometric software into its Enterprise Single Sign-on (SSO) ... two major pharmaceutical companies. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , ...
Cached Biology News:Singapore scientists exploit knowledge of p53 for increasing specificity of cancer treatments 2Male antelopes trick females into extra sex opportunities 2Male antelopes trick females into extra sex opportunities 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 2BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 3BIO-key(R) Biometric Identification Now Incorporated Into Evidian Enterprise Single Sign-On Solution 4
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
versican (H-56)...
... Shimadzu Biotech presents PsiPort Mass ... data review and data acquisition system ... purification for the life science and ... been designed specifically to simplify high ...
Biology Products: